Orally Administered Botanical Therapies Targeting ASD With DeFloria's Jared And Joel Stanley
Source: Drug Delivery Leader
In this episode of Sit and Deliver, host Tom von Gunden talks with Jared Stanley, CEO, and Joel Stanley, board chairman, from DeFloria, a botanical therapeutics development company. Tom talks with the Stanley brothers about cannabinoid-based therapies targeting Autism Spectrum Disorder (ASD). The discussion covers aspects of drug development and delivery including molecule characterization, formulation, and dosing for oral administration, as well as key considerations for commercial-scale production and distribution of regulated botanicals.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.
Subscribe to Drug Delivery Leader
X
Subscribe to Drug Delivery Leader
This website uses cookies to ensure you get the best experience on our website. Learn more